Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases
NEW YORK and LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Akari…
Ajinomoto and XL-protein forge Strategic Alliance to develop PASylated therapeutics applying the Corynex® platform
SAN DIEGO, U.S.A., and FREISING, Germany, 18th December, 2018:…
Horizon Pharma plc and XL-protein GmbH have entered into a collaboration agreement on a potential next-generation biologic for uncontrolled gout using PASylation® technology
FREISING, January 9, 2018 /XL-protein/ -- Horizon Pharma plc…